Founded in 2006, Oncimmune is a leading immuno diagnostics developer that is committed to advancing early cancer detection through its EarlyCDT platform technology. The company's mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. Oncimmune's metro Kansas City laboratory is CLIA-certified, and the company owns a portfolio of patents. With over 200,000 tests already performed for patients worldwide, Oncimmune's immuno diagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. The company's ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune is headquartered in Nottingham, UK, with a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China.